Tvardi Therapeutics, Inc.
TVRD
$1.85
-$0.09-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.10% | 6.47% | -31.63% | -232.64% | 143.50% |
| Total Depreciation and Amortization | -4.17% | 0.00% | 0.00% | 4.35% | -4.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.94% | 5.03% | 1.81% | 102.75% | -318.68% |
| Change in Net Operating Assets | -653.89% | -53.91% | 34.35% | -54.89% | 155.36% |
| Cash from Operations | -57.50% | -3.06% | -33.54% | 27.45% | 23.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.34% | -0.48% | -6.52% | 156.01% | 12.25% |
| Cash from Investing | 3.34% | -0.48% | -6.52% | 156.01% | 12.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -99.07% | -74.58% | 13,933.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -101.77% | 1,607.22% |
| Cash from Financing | -- | -- | 100.31% | -101.31% | 1,636.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -362.74% | -29.09% | -188.83% | -91.64% | 145.65% |